Hereditary Cancer Genetics Panel
The Hereditary Cancer Genetics Panel is an advanced targeted Next-Generation Sequencing (NGS) assay designed to identify germline genetic mutations that significantly increase an individual's lifetime risk of developing cancer. Approximately 5–10% of all cancers stem from inherited pathogenic variants passed down through families. This comprehensive panel screens for hereditary predispositions across major malignancies—including breast, ovarian, colorectal, prostate, and endometrial cancers—enabling early detection and proactive risk management.
Key Features & Advantages
- Early Detection & Preventive Care: Identifies high-risk individuals prior to symptom onset, allowing tailored surveillance regimens (e.g., enhanced MRI, mammography, colonoscopy) or risk-reducing surgical interventions.
- Cascade Family Testing: Uncovering a pathogenic variant in the index patient enables targeted, low-cost genetic screening for first-degree relatives to clarify their systemic risk.
- Guided Precision Oncology: In diagnosed cancer patients, germline status directly informs therapeutic selection, such as utilizing PARP inhibitors for BRCA1/2-deficient tumors.
- Multi-Gene Panel Profiling: Evaluates a broad spectrum of cancer susceptibility loci simultaneously, replacing iterative single-gene tests with a rapid, cost-effective workflow.
Hereditary Cancer NGS Panel vs. Conventional Cancer Screening
| Feature | Hereditary Cancer NGS Panel | Standard Clinical Screening (Mammography, Colonoscopy) |
| Diagnostic Focus | Germline DNA variants predisposing to cancer | Detection of existing physical tumors or tissue lesions |
| Actionable Timeline | Identifies risk years or decades before onset | Detects disease only after structural development |
| Familial Utility | High (Maps hereditary patterns & enables cascade testing) | None (Evaluates individual status at a single point in time) |
| Sample Requirement | Simple Peripheral Blood or Saliva sample | Imaging modalities or invasive physical procedures |
| Therapeutic Impact | Directly informs targeted therapy (e.g., PARP inhibitors) | Guides conventional surgical and chemotherapeutic pathways |
Key Applications
- Hereditary Breast & Ovarian Cancer (HBOC): Comprehensive profiling of BRCA1, BRCA2, PALB2, ATM, and CHEK2 genes.
- Lynch Syndrome & Hereditary Colorectal Cancer: Evaluating MLH1, MSH2, MSH6, PMS2, and EPCAM to stratify colorectal and endometrial cancer risks.
- Familial Prostate & Pancreatic Malignancies: Early surveillance for high-risk individuals with familial clusterings.
- High-Penetrance Cancer Syndromes: Identifying pathogenic mutations in master tumor suppressors, including TP53 (Li-Fraumeni) and PTEN (Cowden Syndrome).
The Nucleus Genetics Advantage: Combining broad target panels fully aligned with NCCN guidelines, ultra-deep NGS coverage, and expert curation by medical geneticists and oncologists, we transform hereditary genomic data into actionable, life-saving clinical strategies.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →